rapidly (Piddock, 2012; Spellberg, Bartlett, & Gilbert, 2013) . These critical concerns lead to a global call for encouraging the discovery of novel drugs that possess distinct molecular structures and offer broad-spectrum functions, as a chance to defeat the AMR problem.
The best-known natural sources for seeking bioactive compounds (eg, antibiotics, anticancer/antitumor agents, biocatalysts, etc.) are plants and microbes. For centuries, some herbs have served as natural medicines in the treatments of human diseases (Alvin, Miller, & Neilan, 2014; Strobel & Daisy, 2003) . These plants synthesize pharmaceutical metabolites that may be stored into their cells and tissues or released in the form of root exudates. Some microbes can live within or in contact with bioactive phytochemicals (Alvin et al., 2014; Nakaew & Sungthong, 2018; Strobel & Daisy, 2003) , while some of which also enable to form the same or similar metabolites to those produced by plants (Alvin et al., 2014; Strobel & Daisy, 2003) .
These plant-associated niches are yet a challenging source for the discovery of new microbial candidates and their novel secondary metabolites.
With the industrial point of view, antibiotic-producing microbes require less space for cultivation, shorter time for biosynthesis, and offer higher flexibility in further biotechnological developments.
Among the microbial producers, actinobacteria are well-known cell factories for drug discovery, especially for those belonging to the genus Streptomyces (Bentley et al., 2002; Tiwari & Gupta, 2012) .
More than two-thirds of all existing natural antibiotics derive from this actinobacterial genus (Bentley et al., 2002) . Streptomyces is a well-explored genus, which consists of 848 species and 38 subspecies, referring to the list of prokaryotic names with standing in nomenclature (http://www.bacterio.net/streptomyces.html) during the time of writing this article. Regarding these high numbers of published Streptomyces members, the recent trend of drug discovery is more focusing on other microbial resources, such as non-Streptomyces actinobacteria, so-called "rare actinomycetes" with the aim to avoid the repetitive finding of the formerly found bioactive metabolites (Tiwari & Gupta, 2012) . However, hitherto, it is just a minority of microbes discovered, while the majority of them is hidden in nature and waiting for exploration.
Streptomyces sp. TM32 was isolated based on the concept of plant-microbe interactions from the rhizosphere soil of turmeric (Curcuma longa L.), a rhizomatous and herbaceous plant, often used in cooking (Nakaew, Rangjaroen, & Sungthong, 2015) . A preliminary identification of TM32 using its 16S rRNA gene sequence revealed the closest phylogenetic relation to Streptomyces sioyaensis DSM 40032 T , a producer of a peptide thiazole antibiotic, siomycin A, possessing both antibacterial and anticancer functions (Gartel, 2013; Tori et al., 1979) . TM32 showed strong antifungal activity and was proven for its plant growth-promoting (PGP) potentials in the suppression of phytopathogenic fungus, Rigidoporus sp. (Nakaew et al., 2015) .
In this study, we aim to report some interesting bioactivities and the draft genomes of the type strain, S. sioyaensis DSM 40032 T , and our emerging strain, TM32. We also unveil the biotechnological treasures in both genomes by employing some bioinformatics tools and discuss the novelty of TM32 based on a set of comparative genome data.
| MATERIAL S AND ME THODS
The antimicrobial activities of crude extracts derived from DSM 40032 T (type strain) or TM32 were tested against either bacteria or fungi and some of which are pathogens of human and plant (Table 1) . Each Streptomyces strain was grown in Hickey-Tresner agar at 30°C for 7 days, which was transferred to grow further in The antimicrobial activity was determined into five levels (excellent ++++, very good +++, good ++, fair +, and no activity −). The value in parenthesis refers to the average size (ø mm) ± standard deviation of the inhibitory zones derived from the duplicate antagonism assays.
were divided into two proportions and one of which was heated by autoclaving at 121°C, 15 psi for 15 min.
Both nonheated and heated crude extracts were dissolved with dimethyl sulfoxide (DMSO) and tested for their antimicrobial activities by the paper disk-diffusion method described elsewhere (Nakaew, Sungthong, Ortega-Calvo, & Lumyong, 2012 (Gurevich, Saveliev, Vyahhi, & Tesler, 2013) . The gene annotation analysis was carried out based on all contigs of each genome using Prokka (Seemann, 2014) . The secondary metabolite-related genes and gene clusters present in the genomes were predicted using antiSMASH 3.0 (Weber et al., 2015) . 
| RE SULTS
The crude extracts provided by ethyl acetate extraction of both Streptomyces strains did not show antimicrobial activity against the test Gram-negative bacterium, Escherichia coli TISTR 887 (Table 1) . (Table 1) . However, TM32 lacks the exo-β-1,3-glucanase gene, which is present in DSM 40032 T 's chromosome.
The absence of the glucanase gene was concordant to the phenotype of TM32 previously observed by an in vitro enzymatic assay (Nakaew et al., 2015) .
DSM 40032 T has a higher number (45) of secondary metabolite-related gene clusters than TM32 (29 gene clusters) ( Table 4 ).
Both strains have a siomycin-encoding gene cluster in their genomes, which is a unique characteristic of S. sioyaensis (Gartel, 2013; Tori et al., 1979 a MIBiG refers to "Minimum Information about a Biosynthetic Gene cluster" in the antiSMASH 3.0 (Weber et al., 2015) . b The presence (+) or absence (−) of each gene cluster is determined, while the value indicated in the parenthesis is the similarity percentage to the known cluster or the number of cluster found.
